Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764428 | 0.90 | BDKRB1 (0.51) | BDKRB1MAPK14CYP3A4SLC22A12 | |
| SCHEMBL765805 | 0.90 | BDKRB1 (0.49) | BDKRB1MAPK14CYP3A4PTGER4SLC22A12 | |
| SCHEMBL764480 | 0.90 | BDKRB1 (0.53) | BDKRB1MAPK14CYP3A4SLC22A12CHRM4 | |
| SCHEMBL765846 | 0.90 | BDKRB1 (0.49) | BDKRB1MAPK14CYP3A4PTGDR2 | |
| SCHEMBL765656 | 0.90 | BDKRB1 (0.49) | BDKRB1MAPK14CYP3A4PTGER4PTGER2 | |
| SCHEMBL765845 | 0.89 | MAPK14 (0.58) | BDKRB1MAPK14CYP3A4 | |
| SCHEMBL765145 | 0.89 | BDKRB1 (0.48) | BDKRB1MAPK14CYP3A4PTGDR2 | |
| SCHEMBL765204 | 0.87 | BDKRB1 (0.51) | BDKRB1MAPK14CYP3A4PTGER4PTGER2 | |
| SCHEMBL10121385 | 0.87 | BDKRB1 (0.53) | BDKRB1MAPK14CYP3A4PTGER4PTGER2 | |
| SCHEMBL765831 | 0.87 | BDKRB1 (0.51) | BDKRB1MAPK14CYP3A4PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | BDKRB1 1/4885MAPK14 1751/4885CYP3A4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.